News

Since the emergence of the SARS-CoV-2 pandemic in particular, news in the infectious disease drug and medical device pipeline has moved at an accelerated pace.

Broncolin S.A. de C.V is voluntarily recalling all lots of Herbacil Antiseptic Hand Sanitizer 70% Alcohol to the consumer level. The products are being recalled due to the potential presence of methanol (wood alcohol).

New findings show "structural inequities" among the US and UK frontline responders first infected months ago.

Dr. Anthony Fauci, CDC's Dr. Robert Redfield, & HHS' Admiral Brett Giroir spoke at a congressional hearing on coordinating the future of the national coronavirus response.

GSK, Sanofi were selected by US Operation Warp Speed to provide a large supply.

A look at the history of vaccines, our society's current standing in public health and vaccine preparedness, and what may come in the near future.

What role does new research play in combating public vaccination concerns?

Peter Hotez, MD, PhD, recently authored a paper proposing a federally directed but state-adaptive reopening that aims for acceptable national suppression by October 1.

IDSA, HIVMA request they be included in ongoing COVID-19 clinical trials.

Here is a compilation of the COVID-19 vaccine candidates that have achieved FDA Emergency Use Authorization, other approvals, and are in phases 1-3.

RedHill Biopharma has initiated a global phase 2/3 study in order to evaluate the use of opaganib in patients with severe COVID-19.

On Tuesday, Cain was said to be recovering, possibly reflecting the complex immune system stages of COVID-19 disease course.

Why reducing pandemic research and response to yes-or-no outcomes is harming public health.

MJH Life Sciences is presenting a webinar today on this important topic.

People with travel links to China, Iran, and Italy may have accounted for nearly two-thirds of early COVID-19 cases in affected countries.

The method extracts SARS-CoV-2 RNA with the Mag-Bind Viral RNA Xpress Kit and the Hamilton MagEx STAR.

Dr. Adam Brufsky, an oncologist, compares viral and cancer immunity. Dr. Patrick Soon-Shiong connects the relation to COVID-19 vaccine research.

What should be anticipated in effectiveness and implication for the leading candidates.

Roche’s tocilizumab did not improve clinical status in hospitalized adult patients with severe COVID-19 associated pneumonia.

Infectious disease specialists explain how long term international cooperation with impacted societies can help to stop the cycle of Ebola outbreaks.

Nearly half of all the people living with HIV are over the age of 50, so age-related comorbidities are becoming a factor.

What happens if we don't get a COVID-19 vaccine? Patrick Soon-Shiong, MD, describes another potential route for research efforts, which could also supplement vaccine development.

One cardiologist speaks about what she witnessed in her NYC hospital including how the virus can be multi-organ and the development of COVID-19 diagnostic protocols.

A cohort assessment of New York-based deliveries from SARS-CoV-2 positive mothers showed no infants were infected nor symptomatic after 2 weeks.

A new modeling study reveals that transmission rates decline if people get their results early and quickly notify contacts of potential exposure.

Dr. Patrick Soon-Shiong and Dr. Adam Brufsky move on from the messenger RNA candidates to the adenovirus vaccines.

The federal agency gives approval for technology company’s test that supports unmonitored testing.

Dr. Patrick Soon-Shiong, Chairman and CEO of ImmunityBio, explains why T-cell immunity could be an important metric when evaluating experimental COVID-19 vaccines.